Literature DB >> 28264880

Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Miguel Moutinho1, Gary E Landreth2.   

Abstract

Alzheimer's disease (AD) is characterized by an extensive accumulation of amyloid-β (Aβ) peptide, which triggers a set of deleterious processes, including synaptic dysfunction, inflammation, and neuronal injury, leading to neuronal loss and cognitive impairment. A large body of evidence supports that nuclear receptor (NR) activation could be a promising therapeutic approach for AD. NRs are ligand-activated transcription factors that regulate gene expression and have cell type-specific effects. In this review, we discuss the mechanisms that underlie the beneficial effects of NRs in AD. Moreover, we summarize studies reported in the last 10-15 years and their major outcomes arising from the pharmacological targeting of NRs in AD animal models. The dissection of the pathways regulated by NRs in the context of AD is of importance in identifying novel and effective therapeutic strategies.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  inflammation; neurodegeneration; neuroprotection; nuclear receptors/liver X receptor; nuclear receptors/peroxisome proliferator-activated receptor; nuclear receptors/retinoic acid receptor; nuclear receptors/retinoid X receptor

Mesh:

Substances:

Year:  2017        PMID: 28264880      PMCID: PMC5625128          DOI: 10.1194/jlr.R075556

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  139 in total

1.  Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model.

Authors:  Daniel W Wesson; Anne H Borkowski; Gary E Landreth; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

2.  PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice.

Authors:  Junya Toba; Miyu Nikkuni; Masato Ishizeki; Aya Yoshii; Naoto Watamura; Takafumi Inoue; Toshio Ohshima
Journal:  Biochem Biophys Res Commun       Date:  2016-04-05       Impact factor: 3.575

3.  ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

Authors:  James J Donkin; Sophie Stukas; Veronica Hirsch-Reinshagen; Dhananjay Namjoshi; Anna Wilkinson; Sharon May; Jeniffer Chan; Jianjia Fan; Jon Collins; Cheryl L Wellington
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

4.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

5.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Ashleigh R Price; Guilian Xu; Zoe B Siemienski; Lisa A Smithson; David R Borchelt; Todd E Golde; Kevin M Felsenstein
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

6.  β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway.

Authors:  Yujie Cheng; Zhi Dong; Sha Liu
Journal:  Pharmacology       Date:  2014-08-26       Impact factor: 2.547

Review 7.  RXR: from partnership to leadership in metabolic regulations.

Authors:  Béatrice Desvergne
Journal:  Vitam Horm       Date:  2007       Impact factor: 3.421

8.  Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis.

Authors:  Dick Terwel; Knut R Steffensen; Philip B Verghese; Markus P Kummer; Jan-Åke Gustafsson; David M Holtzman; Michael T Heneka
Journal:  J Neurosci       Date:  2011-05-11       Impact factor: 6.167

9.  Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.

Authors:  Tarja Malm; Monica Mariani; Lauren J Donovan; Lee Neilson; Gary E Landreth
Journal:  J Neuroinflammation       Date:  2015-01-16       Impact factor: 9.587

10.  A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.

Authors:  Yu Liang; Suizhen Lin; Thomas P Beyer; Youyan Zhang; Xin Wu; Kelly R Bales; Ronald B DeMattos; Patrick C May; Shuyu Dan Li; Xian-Cheng Jiang; Patrick I Eacho; Guoqing Cao; Steven M Paul
Journal:  J Neurochem       Date:  2004-02       Impact factor: 5.372

View more
  25 in total

Review 1.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

2.  Bexarotene, a Selective RXRα Agonist, Reverses Hypotension Associated with Inflammation and Tissue Injury in a Rat Model of Septic Shock.

Authors:  Bahar Tunctan; Sefika P Kucukkavruk; Meryem Temiz-Resitoglu; Demet S Guden; Ayse N Sari; Seyhan Sahan-Firat
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

3.  Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer's Disease iPSC-Derived Neural Stem Cells.

Authors:  Patricia Martín-Maestro; Andrew Sproul; Hector Martinez; Dominik Paquet; Meri Gerges; Scott Noggle; Anatoly A Starkov
Journal:  Mol Neurobiol       Date:  2019-06-16       Impact factor: 5.590

Review 4.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 5.  Cellular cholesterol homeostasis and Alzheimer's disease.

Authors:  Ta-Yuan Chang; Yoshio Yamauchi; Mazahir T Hasan; Catherine Chang
Journal:  J Lipid Res       Date:  2017-03-15       Impact factor: 5.922

Review 6.  Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.

Authors:  Cutler T Lewandowski; Juan Maldonado Weng; Mary Jo LaDu
Journal:  Neurobiol Dis       Date:  2020-02-20       Impact factor: 5.996

7.  Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells.

Authors:  Wei Wang; Ken-Ichi Nakashima; Takao Hirai; Makoto Inoue
Journal:  J Nat Med       Date:  2018-10-30       Impact factor: 2.343

8.  LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target.

Authors:  Mayur Choudhary; Ebraheim N Ismail; Pei-Li Yao; Faryan Tayyari; Roxana A Radu; Steven Nusinowitz; Michael E Boulton; Rajendra S Apte; Jeffrey W Ruberti; James T Handa; Peter Tontonoz; Goldis Malek
Journal:  JCI Insight       Date:  2020-01-16

9.  Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Authors:  Miguel Moutinho; Juan F Codocedo; Shweta S Puntambekar; Gary E Landreth
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-12       Impact factor: 13.820

10.  Anti-inflammatory effects of naturally occurring retinoid X receptor agonists isolated from Sophora tonkinensis Gagnep. via retinoid X receptor/liver X receptor heterodimers.

Authors:  Wei Wang; Ken-Ichi Nakashima; Takao Hirai; Makoto Inoue
Journal:  J Nat Med       Date:  2019-01-17       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.